Most 503A compounding pharmacies assign a beyond-use date (BUD) of 30 days refrigerated, but this can vary
Insulin signals the body to store glucose as fat
About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
Evaluation of muscle amounts Clinical trials of semaglutide have reported a decrease in muscle mass, which increases the risk of sarcopenia, particularly in skeletal muscle [37]
Ensure all packaging, components, and seals remain intact
Another approach could be to use an absorption enhancer